An Update on the Role of Markers of Inflammation in Atherosclerosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
1) Corrado E, Novo S: Role of inflammation and infection in vascular disease. Acta Chir Belg, 2005: 105: 567-579
3) Ridker PM: Inflammation, Infection, and Cardiovascular Risk: How Good Is the Clinical Evidence? Circulation, 1998; 97: 1671-1674
4) Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circula-tion, 2003; 107: 363-369
5) Maresca G, Di Blasio A, Marchioli R, Di Minno G: Mea-suring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol, 1999; 19: 1368-1377
7) Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G: Arterial wall thickness is associated with preva-lent cardiovascular disease in middle-aged adults. The Ath-erosclerosis Risk in Communities (ARIC) Study. Stroke, 1995; 26: 386-391
8) Bots ML, Moons KG, Hollander M, Hoffman A, Koud-staal PJ, Grobbee DE, Breteler MM, Whitman JC: Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circula-tion, 1997; 96: 1432-1437
13) Rizzo M, Corrado E, Coppola G, Muratori I, Novo S: Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: the role of C-reactive protein. J Investig Med, 2008; 56: 32-40
14) Rizzo M, Corrado E, Coppola G, Muratori I, Mezzani A, Novo G, Novo S: The predictive role of C-reactive pro-tein in subjects with hypertension and subclinical athero-sclerosis. Intern Med J 2009 Mar 23. (Epub ahead of print)
17) Rydén L, Standl E, Bartnik M, Van den Berghe G, Better-idge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrain-sdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Mon-teiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardio-vascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardio-vascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Associ-ation for the Study of Diabetes (EASD). Eu Heart J, 2007; 28: 88-136
18) National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421
19) Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: pro-atherogenic HDL--an evolving field. Nat Clin Pract Endo-crinol Metab, 2006; 2: 504-511
22) Martínez-Vila E, Páramo JA, Beloqui O, Orbe J, Irimia P, Colina I, Monreal I, Benito A, Barba J, Zubieta JL, Diez J: Independent Association of Fibrinogen with Carotid Intima-Media Thickness in Asymptomatic Subjects. Cere-brovasc Dis, 2003; 16: 356-362
23) Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med, 1993; 118: 956-963
27) Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol, 1997; 17: 1121-1127
28) Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reac-tive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000; 342: 836-843
30) Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, Pravastatin, and the risk of coronary events after myocar-dial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98: 839-844
37) Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001; 103: 1933-1935
38) Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angio-graphically severe coronary artery disease. J Am Coll Car-diol, 2000; 36: 1774-1780
40) Ridker PM, Cushman M, Stampfer JS, Tracy RP, Hen-nekens CH: Inflammation, Aspirin, and the Risk of Car-diovascular Disease in Apparently Healthy Men. N Engl J Med, 1997; 336: 973-979
41) de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C: Mod-ulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidemia. Thromb Haemost, 1997; 77: 75-79
42) Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R, Effects of fluvastatin and Bezafibrate combination on plasma fibrinogen, t-plas-minogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipid-emia (FACT study) Fluvastatin alone and in combination treatment. Thromb Haemost, 2000; 83: 549-553